Drug Companies

Prevacus Eli Lilly and Novo Nordisk Johnson & Johnson Bristol Myers Squibb Novartis Biogen

Johnson & Johnson Exceeds Q4 Expectations with Strong Cancer Drug Sales

The pharmaceutical giant reports a 5.3% revenue increase, bolstered by Darzalex sales, while forecasting challenges in 2025 due to generics and currency impacts.

6 ARTICLES

last yr.

Novartis Acquires MorphoSys for $2.9 Billion, Expanding Cancer Drug Portfolio

6 ARTICLES

last yr.

Bristol Myers Squibb Acquires RayzeBio for $4.1 Billion